Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, double blind, double dummy, multicenter, parallel controlled clinical trial, the investigators objective is to evaluate the efficacy and safety of Qizhi Weitong granules in the treatment of functional dyspepsia.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Treatments: Citric Acid; Mosapride

Criteria

Inclusion Criteria:

1. Metting the diagnostic criteria of functional dyspepsia in Rome IV.

2. The subjects were informed, and the subjects voluntarily signed informed consent.

3. The subjects have reading ability.

Exclusion Criteria:

1. Patients suffering from gastric ulcer, gastroscopy see bleeding and mucosal erosion, pathological examination showed atrophy of gastric mucosa, intestinal metaplasia or dysplasia.

2. Patients with Hp infection positive.

3. Patients with gastroesophageal reflux disease.

4. Patients with digestive system organic lesions.

5. The patient had a history of stomach or abdominal surgery.

6. Patients had taken the relevant drugs in the past 2 weeks.

7. Patients suffering from severe illness affecting survival.

8. Pregnant or lactating women.

9. Participating in clinical trials of other drugs.

10. Long term using of sedative hypnotics.

11. Suspected or true alcohol, drug abuse history.